-
PURDUE PHARMACEUTICAL PRODUCTS L.P. et al v. ACTAVIS ELIZABETH LLC DC CAFC
- 2:12-cv-05311
- D.N.J.
- Judge: Jose L. Linares
+1
- Filed: 08/23/2012
- Closed: 04/09/2015
- Latest Docket Entry: 09/14/2016
- PACER
- Docket updated daily
3
Plaintiffs
1
Defendant
1
Accused
Product
3
Patents-in-Suit
960
Days in
Litigation
-
PURDUE PHARMACEUTICAL PRODUCTS L.P. et al v. ACTAVIS ELIZABETH LLC DC CAFC
- 2:12-cv-05311
- D.N.J.
- Judge: Jose L. Linares
+1
- Filed: 08/23/2012
- Closed: 04/09/2015
- Latest Docket Entry: 09/14/2016
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 9 |
The method of claim 1, wherein the buffer comprises a carbonate buffer and a bicarbonate buffer.
|
Invalid (103)
Entry 395 |
| 16 |
The method of claim 1, wherein the zolpidem or pharmaceutically acceptable salt thereof is in an amount from about 1 mg to about 5 mg.
|
Invalid (103)
Entry 395 |
| 17 |
The method of claim 1, wherein the zolpidem or pharmaceutically acceptable salt thereof is in an amount from about 2 mg to about 5 mg.
|
Invalid (103)
Entry 395 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 8 |
The method of claim 1, wherein the pharmaceutical composition comprises about 3.5 mg of zolpidem hemitartrate.
|
Invalid (103)
Entry 395 |
| 10 |
The method of claim 8, wherein the pharmaceutical composition provides delivery of zolpidem across the patient's oral mucosa.
|
Invalid (103)
Entry 395 |
| 18 |
The method of claim 12, wherein the pharmaceutical composition comprises about 1.75 mg of zolpidem hemitartrate.
|
Invalid (103)
Entry 395 |
| 19 |
The of claim 18, wherein the pharmaceutical composition provides delivery of zolpidem across the patient's oral mucosa.
|
Invalid (103)
Entry 395 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 11 |
The solid unit dosage composition of claim 1, wherein the zolpidem is delivered across at least one of the sublingual or buccal mucosa.
|
Invalid (103)
Entry 395 |
| 17 |
The solid unit dosage composition as in any of claims 1-6, 15, or 16, containing about 1.75 mg of zolpidem hemitartrate.
|
Invalid (103)
Entry 395 |
| 18 |
The solid unit dosage composition as in any of claims 1-6, 15, or 16, containing about 3.5 mg of zolpidem hemitartrate.
|
Invalid (103)
Entry 395 |
| 22 |
The solid unit dosage composition of claim 12, further comprising a binary buffer system that raises the pH of said subject's saliva to a pH greater than about 8.5, irrespective of the starting pH of saliva.
|
Invalid (103)
Entry 395 |
-
Infringement
Actavis Elizabeth LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Methods of treating middle-of-the-night insomnia | US 8,242,131 B2 |
8, 10, 18, 19
|
Infringement
Entry 395Entry 218 Entry 391 |
Dr. Reddy's Lab., Inc.
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Compositions for treating insomniaGeneric INTERMEZZOMethods of treating middle-of-the-night insomnia | US 8,252,809 B2 |
5, 8, 9, 10, 11, 17, 18, 22
|
Infringement
Entry 395Entry 326 Entry 391 |
Novel Laboratories Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereofMethods of treating middle-of-the-night insomnia | US 7,682,628 B2 |
9, 16, 17
|
Infringement
Entry 395Entry 391 |
| Methods of treating middle-of-the-night insomnia | US 8,242,131 B2 |
8, 10, 18, 19
|
Infringement
Entry 395Entry 391 |
| 1.75mg , 3.5mg zolpidem hemitartrateCompositions for treating insomniaGeneric INTERMEZZOMethods of treating middle-of-the-night insomnia | US 8,252,809 B2 |
5, 8, 9, 10, 11, 17, 18, 22
|
Infringement
Entry 395Entry 326 Entry 366 Entry 391 |
